Patient-Focused Drug Development for Mitochondrial Disease

Time: 3:30 pm
day: Day Two


  • Highlighting the impact of patient input on research and development at Abliva
  • Providing an overview of the multiple therapeutic options for mitochondrial disease being pursued at Abliva
  • Presenting placebo controlled PMD patient data from our lead asset, KL1333